Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176824 | 0.89 | SLC22A12 (0.53) | SLC16A3SLC22A12ESR1PLA2G2APDE5A | |
| SCHEMBL30728962 | 0.83 | SLC16A3 (0.55) | SLC16A3ALDH1A1PDE5ACNR1ACHE | |
| SCHEMBL177096 | 0.81 | SLC22A12 (0.51) | SLC22A12PLA2G2A | |
| SCHEMBL176885 | 0.77 | SLC22A12 (0.52) | SLC16A3SLC22A12ESR1PLA2G2AALDH1A1 | |
| SCHEMBL4029316 | 0.75 | ESR1 (0.67) | ESR1ALDH1A1PDE5APDE4APDE4B | |
| SCHEMBL2240917 | 0.74 | SCN8A (0.50) | ACHE | |
| SCHEMBL257413 | 0.74 | MAOB (0.41) | SLC16A3PDE5AACHE | |
| SCHEMBL1908225 | 0.74 | SLC16A3 (0.52) | SLC16A3ALDH1A1PDE5ACNR1ACHE | |
| SCHEMBL2305448 | 0.74 | SLC22A12 (0.55) | SLC22A12ESR1PLA2G2APDE5ACNR1 | |
| SCHEMBL23399274 | 0.73 | KMT2A (0.42) | ALDH1A1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102171192-A | Indazole compounds | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | claimed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | claimed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | claimed |
| CN-102171192-A | Indazole compounds | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| WO-2010041569-A1 | INDAZOLE COMPOUND | 旭化成ファーマ株式会社 (JP) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | SLC16A3 3584/4885SLC22A12 1721/4885ESR1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.